HUE029098T2 - Lapatinib rák kezelésére - Google Patents
Lapatinib rák kezelésére Download PDFInfo
- Publication number
- HUE029098T2 HUE029098T2 HUE10810654A HUE10810654A HUE029098T2 HU E029098 T2 HUE029098 T2 HU E029098T2 HU E10810654 A HUE10810654 A HU E10810654A HU E10810654 A HUE10810654 A HU E10810654A HU E029098 T2 HUE029098 T2 HU E029098T2
- Authority
- HU
- Hungary
- Prior art keywords
- hla
- lapatinib
- cancer
- treatment
- alt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
Claims (7)
- kapatimb rák kezelésére Szabadalmi igénypontok1. Lapatfmfe, vagy egy gyógyászatiig elfogadható sója vagsjfalany rákja kezelésében történő ajkalmazásrm ahol a humátr aláttyí: agy azonosítlnk, ntintaki tiem tündék kezik a HLADQAI* 0201, %M<|B1 *0202,Mvagy HLA-D&B 1*070! alléi pollmorííz-· mosok közül eggyel vagy többek
- 2, Lapátlóik vagy egy gyógyászati lag elfogadható sofa vagy készítménye, humán alany rákjának 1. igénypont szerinti kezelésében történd alkalmazásra, ahol a humán alanyt úgy azonosítjuk, mint aki mentes sILMlil *0701J11. A-DQA i*0201,.Mvagy .HLA-DQBI mm alléi poliiimrílzmusok közül legalább kettőtől. A Lapatinib, vagy egy iyógyásMiia|®ifogááhafo sója vágy készitmAiym humán alany rákjának I. vagy 2. igénypont, szerinti kezelésében történő alkalmazásra, ahol a iapatíníbet, vagy gyógyászati lag el fogadható sóját vagy készítményét legalább egy további rákellenes szerrel együtt adagoljuk,
- 4. Lapatinib, vagy egy gyógyászati lag elfogadható sója vágy készítménye, humán alany rákjának 3, igénypont szerinti kezelésében történő alkalmazásra, ahol a legalább Agy rákéllenes szer trastuzurnab, capecitabine, paclitaxel, carboplatim pazopanib és letrozole közül választott. 5, kapatimb. vagy egy gyogyászaíilag elfogadható sója vagy készítménye, humán alanyok populációjának rákja kezelésében történd alkalmazásra, ahol a kezelt humán alanyok: rákban szénvedö humán alanyok kiindulási populációjából kerülnek kiviktSztásra. és az alanyoknak a ilildidásí popul,knoiw \>n, menüm csökkentet* sz,vált ka tendelkezík M: A-DQA1 *0201. BLA-DQB 1*0202. és Hl.A-ORBPÜ/0! közül választott I IkA polimorf allélekkel. 6,1 apatímb, vagy egy gyógyászatilag elfogadható sója vagy készítménye, rákban szenvedd humán alanyok 1--Ó, igénypontók bármelyike szerinti kezelésében történő alkaímazásrm ahol a humán, alanyt így azorioSltotnfo^ aki ugyancsak mentes a TMXBrsl2l S38SS és/vagy fsl 7201023 poiimnrhzmustól éá/vsgy genotípustóL
- 7. Kisegítő eljárávS rákban szenvedő human alanynak iapatíulbre, vagy egy győgyászaüiug elfogadható sójáravagyilsaitmlgyére mutatott h^piotoxkltásának:#l:^|fWs|res melynek során meghatározzuk, hogy a humán alany rendelkezik-e SiLA-D'QM *fpis HLA-DQBl *0202. és !ILA4MlB)?ö közöl választott :1LA genotípussal, ahol az ilyen fi LA genotípus jelenléte azt jelzi, hog}' a humán alany fokozott vesAKnek van kitéve iapathy vagy egy gyógyászatüag elfogadható sója vagy készítménye által okozott hepatoloxídtásnak, az; általános populáeíÓnál várható veszéllyel összehasonlítva. :|, A 7, Igénypont szerinti e|áráíá melynek során: továbbá összofoggesbe hozzuk, egy HLÁ~ DQAI*Ö201, BLADQfíl * 0202, és/vagy Hi.A-ÖRM*07tl; alléi kimutatását a lapatiníb, vágy égy győgyászátilág élfopílhátó sója vagy készítménye által okozott Impafotoxichás megnövekedőn v eszélyéveí, fi: A 7. vagy 8. l|ÉíypOltf:§Z«ábl!-eljárás,·mpfpiek során továbbá meghatározzuk, hogy az alany rendelkezik-e egy BLAB* 4403 évvagy TNXB, rsi2ÍS3Í55 és/vagy rsí72§?$23 genö-típussal. 10. A 7-9. igénypontok bármelyike szerinti eljárás, melynek során továbbá meghatározzák, hogy az alany DQ2.2. szeropozitív-e.
- 11. Eljárás lapadnibbel, vagy egy gyógyászatilag elfogadható sójával vagy készHményévei végzett kezékM eljárás során follépő hepatotoxidlás megnövekedőn veszélyének kitett humán alany azonosítására, melynek során: a. az alanytól vett bicílégimanintán genotípízliási eltárásí végzünk annak megállapítására, hogy a humán alany I II.A genotípusa tartalmazóé BLA-ÛCIAfoOlb:!, IILA-ÖC^B 1^0202, vagy MLAïdiffll* ÖTÖlIiLAÄzül választott valamely állóit; b. *0202, és/vagy BLÂ-DE.B1 *0701 alléit; m o. összeftlgglsbe hozzuk a kttnutafob idLA-DOA:foÓ2#ís MEA~D<|B 1*0202, és/vagy HLAv DREI *0701 abéleket a lapatíníbbei, vagy egy győgyászaidag elfogadható sójával vagy ke·· szitmfnyével vépet terápiás : kezelési e|árás megnövekedőit amikor nota voltkimnmíható^ίΑΦ^ΑΙ^ΟΧΗ. Hl V PQBláW ósxag> Hl M>RB1M)70Í ellőlek IS. A llóigénypoMázednti; & httmáb· alnny HkAH'iQA l*M)l él HLA- PQ1I*O202 polimörli^pmssal tgpÄfcteöÖÄteÄ
- 13. À I I. vagy 12. igénypont szerinti eljárás, melyek során továbbá«'Ísítpbá-afeáytöi·^ biológiai minláu genotiplzálási technikát végzünk «· a&âlanÿ mdoikézik-e Ί'ΝΧΒ rs 12153855 éávagy ts l 720?§23:g©notipassai? és aTMXB mí2i 53855 és/vagy rsl?20.7923::pm50|^Sî:asMê%#Â hozzük a lapatiniíbheb vagy egy gyógyászatiig elfogadható s^àya|-i^;itésÂi^^é-vég^î''^^: ke^é* eljárás során fellépő oepakhoxiekás megnövékédéti veszélyét; a* olyas veszéllyek rémkor nepa volt kiputtatható mXB rsí2153:855 és/vagy rsl72í>7923: genottpme
- 14. Lapatinib, vagy egy gyógyászatiiag;élíbgadható sófa vagy készúmenye.egy humán alany Hó. igénypontok bármelyiké szerinti rák elleni kezelésében vagy a? M3. igénypontok bán melyike szerinti e.lJ^^feàsi'Âésô'alkaî.ntpàaia,: ahol az many lóQSá, szeropozitlvnak bizonyuk. II, Lapatinib. vagy egy gyógyfellag elfogadhat# sója « készítménye, egy rákban szenvedő humán alanynak: 1*6. vagy I4> igénypontok bármelyike szerinti kezelésében vagy 4 Aló.: igénypontok foárnmiyiké szerinti: éljarásban történő aikainihzasm, ahol; a rák mellrák.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23594709P | 2009-08-21 | 2009-08-21 | |
US30756910P | 2010-02-24 | 2010-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE029098T2 true HUE029098T2 (hu) | 2017-02-28 |
Family
ID=43607603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE10810654A HUE029098T2 (hu) | 2009-08-21 | 2010-08-20 | Lapatinib rák kezelésére |
Country Status (26)
Country | Link |
---|---|
US (3) | US20120156200A1 (hu) |
EP (1) | EP2467140B1 (hu) |
JP (1) | JP5876827B2 (hu) |
KR (1) | KR101781658B1 (hu) |
CN (1) | CN102770140B (hu) |
AU (2) | AU2010284092A1 (hu) |
BR (1) | BR112012003653A2 (hu) |
CA (2) | CA2771699C (hu) |
CY (1) | CY1118486T1 (hu) |
DK (1) | DK2467140T3 (hu) |
EA (1) | EA027959B1 (hu) |
ES (1) | ES2589377T3 (hu) |
HR (1) | HRP20161110T1 (hu) |
HU (1) | HUE029098T2 (hu) |
IL (1) | IL218230B (hu) |
LT (1) | LT2467140T (hu) |
ME (1) | ME02492B (hu) |
MX (1) | MX367580B (hu) |
PL (1) | PL2467140T3 (hu) |
PT (1) | PT2467140T (hu) |
RS (1) | RS55074B1 (hu) |
SG (2) | SG10201405039VA (hu) |
SI (1) | SI2467140T1 (hu) |
SM (1) | SMT201600296B (hu) |
WO (1) | WO2011022633A2 (hu) |
ZA (1) | ZA201201110B (hu) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2484678B1 (en) | 2009-09-28 | 2015-01-21 | Qilu Pharmaceutical Co., Ltd | 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors |
BR112014019034A8 (pt) * | 2012-01-31 | 2017-07-11 | Smithkline Beecham Cork Ltd | Método para tratamento de câncer |
GB201403820D0 (en) | 2014-03-04 | 2014-04-16 | Isis Innovation | Assay |
CN104293958B (zh) * | 2014-10-16 | 2016-09-21 | 卫生部北京医院 | 一种预测强直性脊柱炎易感性的试剂盒和方法 |
RU2761249C2 (ru) * | 2016-12-14 | 2021-12-06 | Мерк Шарп энд Доум Корп. | Человеческие генетические маркеры, ассоциированные с ответом на средства для лечения, которые целенаправленно воздействуют на токсин b clostridium difficile |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5871918A (en) | 1996-06-20 | 1999-02-16 | The University Of North Carolina At Chapel Hill | Electrochemical detection of nucleic acid hybridization |
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
JP2000508912A (ja) | 1996-04-19 | 2000-07-18 | スペクトラ バイオメディカル,インコーポレイテッド | 多型形態と複数の表現型との相関付け |
PT912559E (pt) | 1996-07-13 | 2003-03-31 | Glaxo Group Ltd | Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
BR0111947A (pt) | 2000-06-30 | 2003-05-06 | Glaxo Group Ltd | Composto, composição farmacêutica, método para o tratamento de um distúrbio em um mamìfero, uso de um composto e processo para preparar, um composto |
US20070281041A1 (en) * | 2004-03-02 | 2007-12-06 | Introgen Therapeutics, Inc. | Compositions and Methods Involving MDA-7 for the Treatment of Cancer |
WO2005121380A1 (en) * | 2004-06-04 | 2005-12-22 | Smithkline Beecham Corporation | Predictive biomarkers in cancer therapy |
JP2007117085A (ja) * | 2005-09-28 | 2007-05-17 | Genodive Pharma Kk | 塩酸チクロピジンの副作用である肝臓障害の発生危険率の検査方法 |
JPWO2007099852A1 (ja) | 2006-02-23 | 2009-07-16 | 国立大学法人金沢大学 | 固形癌のチロシンキナーゼ阻害剤に対する感受性を検査する方法及び検査キット |
WO2008070448A2 (en) * | 2006-11-22 | 2008-06-12 | Board Of Regents, The University Of Texas System | Cancer-specific promoters |
US20080131887A1 (en) * | 2006-11-30 | 2008-06-05 | Stephan Dietrich A | Genetic Analysis Systems and Methods |
EP2134863B1 (en) * | 2007-03-13 | 2014-05-21 | The Children's Hospital Of Philadelphia | Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis of type 1 diabetes |
-
2010
- 2010-08-20 ES ES10810654.3T patent/ES2589377T3/es active Active
- 2010-08-20 MX MX2012002161A patent/MX367580B/es active IP Right Grant
- 2010-08-20 CN CN201080047795.1A patent/CN102770140B/zh active Active
- 2010-08-20 KR KR1020127007152A patent/KR101781658B1/ko active IP Right Grant
- 2010-08-20 BR BR112012003653A patent/BR112012003653A2/pt not_active IP Right Cessation
- 2010-08-20 DK DK10810654.3T patent/DK2467140T3/en active
- 2010-08-20 WO PCT/US2010/046142 patent/WO2011022633A2/en active Application Filing
- 2010-08-20 EP EP10810654.3A patent/EP2467140B1/en active Active
- 2010-08-20 RS RS20160681A patent/RS55074B1/sr unknown
- 2010-08-20 PT PT108106543T patent/PT2467140T/pt unknown
- 2010-08-20 US US13/391,579 patent/US20120156200A1/en not_active Abandoned
- 2010-08-20 PL PL10810654T patent/PL2467140T3/pl unknown
- 2010-08-20 LT LTEP10810654.3T patent/LT2467140T/lt unknown
- 2010-08-20 AU AU2010284092A patent/AU2010284092A1/en not_active Abandoned
- 2010-08-20 SI SI201031257A patent/SI2467140T1/sl unknown
- 2010-08-20 SG SG10201405039VA patent/SG10201405039VA/en unknown
- 2010-08-20 EA EA201270298A patent/EA027959B1/ru not_active IP Right Cessation
- 2010-08-20 HU HUE10810654A patent/HUE029098T2/hu unknown
- 2010-08-20 CA CA2771699A patent/CA2771699C/en active Active
- 2010-08-20 SG SG2012010658A patent/SG178439A1/en unknown
- 2010-08-20 ME MEP-2016-168A patent/ME02492B/me unknown
- 2010-08-20 JP JP2012525725A patent/JP5876827B2/ja active Active
- 2010-08-20 CA CA3080511A patent/CA3080511C/en active Active
-
2012
- 2012-02-15 ZA ZA2012/01110A patent/ZA201201110B/en unknown
- 2012-02-20 IL IL218230A patent/IL218230B/en active IP Right Grant
-
2014
- 2014-06-17 AU AU2014203270A patent/AU2014203270B2/en not_active Revoked
-
2015
- 2015-02-27 US US14/634,052 patent/US9539257B2/en active Active
-
2016
- 2016-08-30 HR HRP20161110TT patent/HRP20161110T1/hr unknown
- 2016-09-01 SM SM201600296T patent/SMT201600296B/it unknown
- 2016-09-01 CY CY20161100861T patent/CY1118486T1/el unknown
- 2016-11-21 US US15/356,719 patent/US10004742B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101719376B1 (ko) | 연령-관련 황반 변성에서 유전자 다형성 | |
EP2276855B1 (en) | Genetic polymorphisms associated wiith venous thrombosis, methods of detection and uses thereof | |
US10004742B2 (en) | Method of treating cancer | |
WO2009032316A2 (en) | Genetic polymorphisms associated with rheumatoid arhritis, methods of detection and uses thereof | |
EP2217722B1 (en) | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof | |
KR20110106244A (ko) | 간세포암종의 예후 진단용 단일 염기 다형성 | |
AU2013214254B2 (en) | Method of treating cancer | |
LUDWIG et al. | Loss of wild-type MEN1 gene expression in multiple endocrine neoplasia type 1-associated parathyroid adenoma |